Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 5:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 14,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Diabetes, Gestational
Interventions: Physical Activity Intervention, Wellness Education; Behavioral · Other
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Pain, Postoperative
Interventions: N1539, Placebo; Drug
Lead sponsor: Baudax Bio; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 10
States / cities: Florence, Alabama • Mobile, Alabama • Miami, Florida + 6 more

Conditions: Dermatitis, Atopic, Eczema
Interventions: CC-93538, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 62
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Fountain Valley, California + 28 more

Conditions: Coronary Artery Disease
Interventions: RespirAct; Device
Lead sponsor: Indiana University; Other
Eligibility: 45 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Infertility
Interventions: GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Chemotherapy Side Effects, Taste, Altered
Interventions: Taste Alteration Self-Assessment, Taste Alternation Self-Management; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Nephropathy, Chronic Kidney Disease
Interventions: Zemplar (paricalcitol) capsules, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 20 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more

Conditions: Hypertriglyceridemia, Familial Chylomicronemia Syndrome
Interventions: RN0361; Drug
Lead sponsor: Ikaria Bioscience Pty Ltd; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Tamarac, Florida • Versailles, Kentucky • Dilworth, Minnesota + 3 more

Conditions: Gastroenteritis Escherichia Coli
Interventions: Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Participants
Interventions: PF-07258669, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Opioid-induced Constipation
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 96 more

Conditions: SARS-CoV2 Infection
Interventions: Testing for SARS CoV2 RNA; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 99 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Gout, Hyperuricemia
Interventions: SAP-001; Drug
Lead sponsor: Shanton Pharma Co., Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Anaheim, California • South Miami, Florida + 3 more

Conditions: Insomnia Disorder
Interventions: Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more

Conditions: Binge Alcohol Consumption, Suicidal Ideation
Interventions: EA-Avatar, Suicide safety planning app; Behavioral
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years to 29 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Marlborough, Massachusetts • Worcester, Massachusetts

Conditions: Persistent Asthma
Interventions: Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 27
States / cities: Avondale, Arizona • North Hollywood, California • Bradenton, Florida + 21 more

Conditions: Post Operative Pain, Acute
Interventions: Combogesic® tablets, Acetaminophen 500mg, Placebo; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Violence
Interventions: School safety tactics and policies; Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 648 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Post-traumatic Stress Disorder (PTSD), Trauma and Stress Related Disorders, Occupational Stress, Emotional Regulation Difficulties, Anger Problems, Relational Problems, Irritability
Interventions: Brazilian Jiu-Jitsu Program; Behavioral
Lead sponsor: Sam Houston State University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Conroe, Texas

Conditions: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
Interventions: BOTOX, Placebo for BOTOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 40
States / cities: Homewood, Alabama • Mobile, Alabama • Buena Park, California + 32 more

Conditions: Bacterial Infections
Interventions: XNW4107, Imipenem/Cilastatin, placebo; Drug
Lead sponsor: Evopoint Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Major Depressive Disorder
Interventions: PRAX-114, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 30
States / cities: Phoenix, Arizona • Garden Grove, California • Lafayette, California + 27 more

Conditions: Sensorineural Hearing Loss
Interventions: LY3056480; Drug
Lead sponsor: Audion Therapeutics BV; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Chicago, Illinois • New York, New York • Norfolk, Virginia

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, Testosterone, Buspirone hydrochloride; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: San Diego, California • Bradenton, Florida • North Miami, Florida + 9 more

Search by objective public record fields.

The Project Wellness Pilot Feasibility Randomized Controlled Trial

Evaluation of Preoperative N1539 in Colorectal Surgery

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Needle Free Assessment of Myocardial Oxygenation in Healthy Subjects

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

Taste Alterations Study

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Long Term Safety of Naldemedine

Rutgers Pilot for PREDICT- Patient LAB Test

Placebo Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAP-001 in Gout Patients

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

Preliminary Trial of an Avatar Guided Digital Intervention for Emerging Adults

Study of Safety of Foradil in Patients With Persistent Asthma

A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery

Nationwide Study of Firearm Violence Prevention Tactics and Policies in K-12 Schools

Grappling With Trauma: Brazilian Jiu-Jitsu for First Responders

Study of BOTOX Injections to Assess Change in Disease Activity and Adverse Events in Adult Female Participants With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females.

A Clinical Trial of PRAX-114 in Participants With Major Depressive Disorder

A Trial of LY3056480 in Patients With SNLH

Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems